59th Medical Wing at the Wilford Hall Ambulatory Surgical Center (WHASC)
The 59th Medical Wing at the Wilford Hall Ambulatory Surgical Center (WHASC) provides support for research conducted by investigators and their collaborators addressing the unique scientific needs of the Air Force, the Department of Defense and the Nation.
The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.
Principal Investigator(s)
Clarke, William P
Funded by
NIH
Functional selectivity, also known as 'biased agonism', is a term used to describe the ability of drugs, acting at the same receptor subtype, to differentially regulate the activity of each of the multiple signaling cascades coupled to the receptor. The underlying mechanism for functional selectivity is based upon the formation of ligand-specific receptor conformations that are dependent upon ligand structure and that have differential ability to regulate various cellular signal transduction molecules.
The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.
Principal Investigator(s)
Meyer, Andrew Duncan Joseph
Funded by
NIH
My long-term goal is to become a pediatric critical care physician-scientist, a translational researcher committed to eliminate complications from advanced technology used to support critically ill children. My current emphasis is to focus on the pathophysiological basis of the untoward effects of cardiopulmonary bypass (CPB) devices on blood components. The Mentored Patient-Oriented Research Career Development Award (K23) will provide me with time to gather skills and knowledge as a necessary steps toward becoming an established, independent investigator.
The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.
Principal Investigator(s)
Nawrocki, Steffan T
Funded by
NIH
Activation of the oncogene MYC is a frequent event in multiple myeloma (MM) that contributes to refractory/high-risk disease and is therefore an attractive therapeutic target. We previously demonstrated that a novel reovirus formulation for cancer therapy called Reolysin is a promising new agent for patients with MM as it exhibits significant activity in cell lines, primary patient cells, and mouse models of the disease. However, the mechanisms that mediate reovirus sensitivity in MM cells are not well understood.